Back to Journals » Drug Design, Development and Therapy » Volume 11

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy

Authors Graf SA, Garcia JM

Received 23 May 2017

Accepted for publication 30 June 2017

Published 7 August 2017 Volume 2017:11 Pages 2325—2331

DOI https://doi.org/10.2147/DDDT.S110131

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Georgios Panos

Solomon A Graf,1–3 Jose M Garcia4,5

1Veterans Affairs Puget Sound Health Care System, 2Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, 3Clinical Research Division, Fred Hutchinson Cancer Research Center, 4Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, 5Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington School of Medicine, Seattle, WA, USA

Abstract: Cancer anorexia–cachexia syndrome (CACS) is a complex and largely untreatable paraneoplastic complication common in advanced cancer. It is associated with profoundly deleterious effects on quality of life and survival. Since its discovery over a decade ago, anamorelin hydrochloride (anamorelin), a mimetic of the growth hormone secretagogue ghrelin, has shown considerable promise in ameliorating components of CACS when administered to patients with advanced cancer, including loss of lean body mass and reversal of anorexia. This review summarizes the development of anamorelin and its safety and efficacy in clinical investigations. The potential future role of anamorelin in treating CACS is also discussed.

Keywords: anamorelin, cachexia, anorexia, ghrelin, non-small cell lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]